DualityBio Inc.
DualityBio Inc. has 1 licensing announcement in this dataset, dated 2026-08-28.
- Country / operating region
- China
- Ticker
- 09606.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Antibody-drug conjugate research and development
- Website
- en.dualitybiologics.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| DUPAC collaboration ADC programs | 查無 | ADC | 查無 | 2026-08-28 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| DB-1303 / BNT323 | PHASE3 | NCT06340568 | RECRUITING | BioNTech SE | 2026-10-16 |
| DB-1311 / BNT324 | PHASE3 | NCT07365995 | RECRUITING | BioNTech SE | 2026-10-16 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | Genentech | DUPAC collaboration ADC programs | USD 45m | 查無 | > USD 1000m | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Genentech | Worldwide | Tiered royalties on annual net sales of approved collaboration products. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無